ArticleJournal of cancer research and clinical oncology2025
tRF-34-86J8WPMN1E8Y2Q promotes the occurrence and development of gastric cancer by combining with LRAT.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundA large number of studies have demonstrated that tRNA-derived fragments (tRFs) are implicated in the progression and nociception associated with various malignancies. However, the biological role of tRF-34-86J8WPMN1E8Y2Q (tRF-34) in cancer, particularly in gastric cancer (GC), remains elusive and warrants investigation. This study aimed to investigate the clinical and mechanistic significance of tRF-34 in GC pathogenesis and potential as novel biomarker for early detection.
methodsThe quantitative expression levels of tRF-34 in GC cell lines, tissues, and plasma were determined using quantitative real-time polymerase chain reaction (qRT-PCR). Subsequently, the functional impact of tRF-34 downregulation on GC progression was investigated using Cell Counting Kit-8 (CCK-8) assays to assess cell proliferation and transwell assays to evaluate migration and invasion. Downstream target genes of tRF-34 were identified through database analysis and validated using RNA Binding Protein Immunoprecipitation (RIP) experiments.
resultstRF-34 exhibits elevated expression levels in GC tissues cells and preoperative (1 day) plasma compared with normal counterparts and postoperative (10 day) plasma. Also, it was associated with neural and vascular invasion in patients with GC. Moreover, tRF-34 downregulation impedes the proliferative, migratory, and invasive capacities of GC cells. Mechanistically, RIP and bioinformatic analyses demonstrated that tRF-34 directly bound to lecithin retinol acyltransferase (LRAT), and this interaction promoted the progression of GC.
conclusiontRF-34 has high expression specificity in GC and the potential to be a biomarker for early detection. Also, tRF-34 directly binds to LRAT, facilitating GC progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.